Avita Medical
1st Floor, Unex House
132-134 Hills Road
Cambridge
CB2 8PA
United Kingdom
Tel: 44-0-1223 341150
Fax: 44-0-1223-341170
Website: http://www.avitamedical.com/
Email: info.eu@avitamedical.com
274 articles about Avita Medical
-
Investor Webinar Briefing - September 13, 2022
9/13/2022
AVITA Medical, Inc. invites shareholders and prospective investors to attend its investor webinar and presentation by Dr. Mike Perry, CEO, and Michael Holder, CFO, on September 20, 2022 at 3:30pm / September 21, 2022 at 8:30am.
-
AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System
9/12/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company) today announced positive topline results from a pivotal randomized, controlled trial evaluating the safety and effectiveness of the RECELL® System for repigmentation of stable vitiligo lesions.
-
RECELL System Insurance Coverage Begins in Japan for Treatment of Acute Burns
9/1/2022
AVITA Medical, Inc. announced that COSMOTEC, an M3 Group Company, received insurance coverage in Japan for the RECELL® System for the treatment of acute burns.
-
RECELL® System Data to be Presented at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting
8/17/2022
AVITA Medical, Inc. announced that a poster presentation on cell characterization and potential clinical benefits of the RECELL® Autologous Cell Suspension System for the treatment of stable vitiligo will be shared at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting.
-
AVITA Medical Reports Second Quarter 2022 Financial Results
8/11/2022
AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, reported financial results for its second quarter ended June 30, 2022.
-
AVITA Medical Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries using the RECELL® System
8/11/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), today announced topline results from its pivotal randomized, controlled trial evaluating the safety and effectiveness of the RECELL System combined with meshed autograft for reduction of donor skin harvesting in soft tissue reconstruction.
-
AVITA Medical to Announce Second Quarter 2022 Financial Results
7/25/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it will release its second quarter 2022 financial results on Thursday, August 11, 2022.
-
AVITA Medical Reports First Quarter 2022 Financial Results
5/12/2022
AVITA Medical, Inc. reported financial results for its first quarter ended March 31, 2022.
-
AVITA Medical to Announce First Quarter 2022 Financial Results
4/28/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it will release its first quarter 2022 financial results on Thursday, May 12, 2022.
-
Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors
4/21/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that Louis Drapeau has resigned, effective April 29, 2022, from the Company’s Board of Directors.
-
RECELL® System Data to be Presented at the American Burn Association Annual Meeting
4/4/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), announced today that fifteen presentations highlighting the clinical and cost-savings benefits of the RECELL® Autologous Cell Harvesting Device (RECELL® System) for the treatment of burn wounds will be shared at the American Burn Association (ABA) Annual Meeting.
-
RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium
3/23/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), announced today that an abstract highlighting the clinical trial protocol utilizing the RECELL® Autologous Cell Harvesting Device (RECELL® System) to treat vitiligo will be presented at the Global Vitiligo Foundation Annual Scientific Symposium.
-
AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction
3/21/2022
AVITA Medical, Inc. announced that the Biomedical Advanced Research and Development Authority has modified its existing contract with the Company to support AVITA Medical’s clinical trial in soft tissue reconstruction.
-
Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S.
3/2/2022
AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced that they have been awarded a group purchasing agreement with Premier, Inc.
-
AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results
2/28/2022
AVITA Medical, Inc. reported its financial results for the quarter ending December 31, 2021, and its transition period fiscal year from July 1, 2021, to December 31, 2021.
-
The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company
2/23/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to market the RECELL® System in Japan.
-
AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference
2/23/2022
AVITA Medical, Inc. announced that Dr. Mike Perry, CEO, will present at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. Eastern Standard Time.
-
AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use
2/17/2022
AVITA Medical, Inc. announced that the United States Food and Drug Administration has reviewed and approved the premarket approval application supplement for RECELL® Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow.
-
AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results
2/15/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it plans to release its July 1, 2021 to December 31, 2021 financial results after the market closes on Monday, February 28, 2022.
-
RECELL® System Data to be Presented at 44th Annual John A. Boswick Burn & Wound Care SymposiumData presentations highlight broad clinical adoption of the RECELL® System for treatment of burn wounds
1/24/2022
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that six abstracts highlighting the clinical benefits of the RECELL® Autologous Cell Harvesting Device (RECELL® System) have been accepted at the 44th Annual John A. Boswick Burn & Wound Care Symposium.